Effect of Rosiglitazone Maleate on Inflammation Following Cerebral Ischemia/Reperfusion in Rats
- Author:
Nanxiang XIONG
1
;
Fan SUN
;
Hongyang ZHAO
;
Jizhou XIANG
Author Information
1. 华中科技大学同济医学院附属协和医院
- Keywords:
Rosiglitazone Maleate;
rat;
brain ischemia;
myeloperoxidase;
interleukin-6
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2007;27(3):295-298
- CountryChina
- Language:Chinese
-
Abstract:
In order to evaluate the neuroprotective effect of Rosiglitazone Maleate (RSG) against brain ischemic injury, the effects of Rosiglitazone Maleate on the inflammation following cerebral ischemia/reperfusion were investigated. Focal cerebral ischemia was induced by the intraluminal thread for cerebral middle artery (MCA) occlusion. Rosiglitazone Maleate at concentrations of 0.5,2 and 5 mg/kg was infused by intragastric gavage twice immediately and 2 h after MCA occlusion,respectively. The effects of Rosiglitazone Maleate on brain swelling, myeloperoxidase and interleukin-6 mRNA level in brain tissue after MCA occlusion and reperfusion were evaluated. The results showed that as compared with the model control group, RSG (0.5 mg/kg) had no significant influence on brain swelling (P＞0.05), but 2 mg/kg and 5 mg/kg RSG could significantly alleviate brain swelling (P＜0.05). All different doses of RSG could obviously reduce MPO activity in brain tissue after MCA occlusion and reperfusion in a dose-dependent manner. RSG (0.5 and 2 mg/kg) could decrease the expression levels of IL-6 mRNA in brain tissue after MCA occlusion and reperfusion to varying degrees (P＜0.05) with the difference being significant between them. It was concluded that RSG could effectively ameliorate brain ischemic injury after 24 h MCA occlusion and inhibit the inflammatory response after ischemia-reperfusion in this model.
